share_log

10-K: FY2023 Annual Report

10-K: FY2023 Annual Report

10-K:2023財年年報
美股SEC公告 ·  2024/06/07 04:16

Moomoo AI 已提取核心訊息

The company reported a significant improvement in its financial performance for 2023, with net losses decreasing to $29.8M from $95.3M in 2022. Research expenses dramatically reduced to $13 from $159 in the previous year. However, the company's cash position remains critical at $38,000 as of December 31, 2023.The firm has secured several strategic financing arrangements, including a $5M stock purchase agreement with ClearThink, a $110,000 convertible note from LGH Investments, and a $750 promissory note at 12% interest. A notable strategic partnership was established with KR8 AI in January 2024, involving a Master Software Agreement for epigenetic biomarker technology and the issuance of 1.3M shares of Class A Common Stock.The company faces significant challenges, including going concern issues beyond Q3 2024 and NYSE American listing compliance requirements. Material weaknesses in internal controls persist, while multiple financing arrangements carry dilutive potential. The firm continues its research collaboration with CHOP for DNA methylation array software and is developing AI machine learning applications for health and wellness.
The company reported a significant improvement in its financial performance for 2023, with net losses decreasing to $29.8M from $95.3M in 2022. Research expenses dramatically reduced to $13 from $159 in the previous year. However, the company's cash position remains critical at $38,000 as of December 31, 2023.The firm has secured several strategic financing arrangements, including a $5M stock purchase agreement with ClearThink, a $110,000 convertible note from LGH Investments, and a $750 promissory note at 12% interest. A notable strategic partnership was established with KR8 AI in January 2024, involving a Master Software Agreement for epigenetic biomarker technology and the issuance of 1.3M shares of Class A Common Stock.The company faces significant challenges, including going concern issues beyond Q3 2024 and NYSE American listing compliance requirements. Material weaknesses in internal controls persist, while multiple financing arrangements carry dilutive potential. The firm continues its research collaboration with CHOP for DNA methylation array software and is developing AI machine learning applications for health and wellness.
FOXO技術公司(FOXO)已公佈截至2023年12月31日的財務業績和業務發展情況。公司該年未從投資活動中產生現金流量,與前一年投資於內部使用軟件開發的1870美元形成對比。融資活動提供了1168美元的淨現金流入,大幅降低了去年的24289美元。其中包括來自私募和相關方的應收票據/應付票據,抵消了推遲的發行成本。公司的合同義務包括許可協議和高級PIK票據,其貸款本金餘額爲4203美元,處於違約狀態。FOXO的關鍵會計政策涉及股權補償,獎勵按公允價值衡量。公司選擇了可轉換債券的公允價值選項,以更好地反映相關的負債。管理層評估了公司作爲經營實體的能力,承認需要額外的資本和營收產生以緩解其生存能力的重大疑慮。FOXO的未來計劃是採用從2025年1月1日開始實施的新會計準則,並管理可能影響業務運營的風險,例如經濟波動和地緣政治不穩定性。
FOXO技術公司(FOXO)已公佈截至2023年12月31日的財務業績和業務發展情況。公司該年未從投資活動中產生現金流量,與前一年投資於內部使用軟件開發的1870美元形成對比。融資活動提供了1168美元的淨現金流入,大幅降低了去年的24289美元。其中包括來自私募和相關方的應收票據/應付票據,抵消了推遲的發行成本。公司的合同義務包括許可協議和高級PIK票據,其貸款本金餘額爲4203美元,處於違約狀態。FOXO的關鍵會計政策涉及股權補償,獎勵按公允價值衡量。公司選擇了可轉換債券的公允價值選項,以更好地反映相關的負債。管理層評估了公司作爲經營實體的能力,承認需要額外的資本和營收產生以緩解其生存能力的重大疑慮。FOXO的未來計劃是採用從2025年1月1日開始實施的新會計準則,並管理可能影響業務運營的風險,例如經濟波動和地緣政治不穩定性。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息